crepidiaside E | 104778-11-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: crepidiaside E
• 英文别名: picriside A；Ncnuksmlrptjbc-nxtblzeosa-；(3aR,4S,9aS,9bR)-4-hydroxy-6-methyl-3-methylidene-9-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-4,5,9a,9b-tetrahydro-3aH-azuleno[4,5-b]furan-2,7-dione
• CAS: 104778-11-2
• 化学式: C₂₁H₂₆O₁₀
• 分子量: 438.431
• InChiKey: NCNUKSMLRPTJBC-NXTBLZEOSA-N

物化性质

• 沸点：
  769.6±60.0 °C(Predicted)
• 密度：
  1.54±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  163
• 氢给体数：
  5
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  crepidiaside E 在 crude hesperidinase 作用下， 以 水 为溶剂， 反应 3.0h， 生成 山莴苣素
  参考文献：
  名称：

  Sesquiterpene lactones from Picris hieracioides L. var. japonica Regel. I.

  摘要：

  三种新的倍半萜糖苷，苦味苷 A (III)、B (VI) 和 C (VII)，以及乳糖苷 (I)、11β、13-二氢乳糖素 (II)、crepidiaside A (IV) 和 ixerin F (V)，已从 Picris hieracioides L. var. 的甲醇提取物中分离出来。粳稻REGEL（菊科）。新化合物的结构是根据化学和光谱数据确定的。

  DOI：

  10.1248/cpb.34.2518
• 作为产物：
  描述：

  crepidiaside E 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 1.0h， 生成 对羟基苯乙酸 、 crepidiaside E
  参考文献：
  名称：

  Sesquiterpene glycosides from Crepidiastrum keiskeanum Nakai.

  摘要：

  从 Crepidiastrum keiskeanum NAKAI（菊科）中分离出五种新的愈创木烷型倍半萜糖苷。根据光谱数据和几种化学转化阐明了它们的结构。

  DOI：

  10.1248/cpb.33.4906

文献信息

• LIGHT SOURCE FOR PLANT CULTIVATION
  申请人：Seoul Viosys Co., Ltd.

  公开号：EP3841869A1

  公开（公告）日：2021-06-30

  A plant cultivation light source is turned on or turned off depending on a light period and a dark period of a plant. When a portion of the light period is referred to as a first period and the other portion of the light period is referred to as a second period, the first period and the second period are alternately provided with each other, and lights having different wavelengths from each other are provided to the plant in the first and second periods, thereby increasing a content of an active ingredient in the plant.

  植物栽培光源的开启或关闭取决于植物的光照期和黑暗期。当一部分光照时间段被称为第一光照时间段，另一部分光照时间段被称为第二光照时间段时，第一光照时间段和第二光照时间段相互交替，在第一光照时间段和第二光照时间段向植物提供波长不同的光照，从而增加植物中有效成分的含量。
• Method for treating a protozoal infection
  申请人：Reid Christopher Brian

  公开号：US10561650B2

  公开（公告）日：2020-02-18

  A method for reducing motility and number of L. donovani cells, said method comprising contacting the L. donovani cells with an effective amount of a composition, the composition comprising a combination of metronidazole and itraconazole, wherein the effective amount is sufficient to reduce motility of the L. donovani cells.

  一种降低唐诺瓦尼氏菌细胞活力和数量的方法，所述方法包括将唐诺瓦尼氏菌细胞与有效量的组合物接触，所述组合物包括甲硝唑和伊曲康唑的组合，其中有效量足以降低唐诺瓦尼氏菌细胞的活力。
• US20140271923A1
  申请人：——

  公开号：US20140271923A1

  公开（公告）日：2014-09-18
• METHOD FOR TREATING A PROTOZOAL INFECTION
  申请人：REID Christopher Brian

  公开号：US20160354370A1

  公开（公告）日：2016-12-08

  Patients inflicted with various clustering chronic diseases require treatment with multiple drugs having distinct mechanisms of action. Accordingly, patients with multiple conditions suffer from cumulative side effects of multiple drugs as well as drug-drug interactions. Embodiments, agents, compounds or drugs of the present invention, such as sesquiterpenes, e.g., Zerumbone, replace an equal or larger number of approved drugs during patient treatment. Examples of disorders prevented or ameliorated by administration of the formulations of this invention include but are not limited to inflammatory diseases that may be, oncological, genetic, ischemic, infectious, neurological, hematological, ophthalmological, rheumatoid, orthopedic, neurological, hematological, kidney, vascular, dermatological, gynecological, or obstetric. The present invention further relates to a method of identifying agents, compounds or drugs useful in preventing or treating CDCP related diseases and conditions as well as other disorders, diseases and conditions treatable or preventable by the same agents, compounds or drugs.
• Compositions of Natural Extracts and Use Thereof in Methods for Preventing or Treating Diseases
  申请人：REID Christopher Brian

  公开号：US20190224193A1

  公开（公告）日：2019-07-25

  A composition for reducing miR-3120 expression in a cell or tissue of a subject comprises at least one oil or extract selected from a group comprising an orange, frankincense and cannabis oil or extract. A method for reducing miR-3120 expression in a cell or tissue of a subject comprises administering to the subject a composition comprising at least one oil or extract selected from the group comprising an orange, frankincense and cannabis oil or extract.